These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32856068)

  • 1. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
    Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
    Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idelalisib for treatment of B-cell malignancies.
    Do B; Mace M; Rexwinkle A
    Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
    Ramanathan S; Jin F; Sharma S; Kearney BP
    Clin Pharmacokinet; 2016 Jan; 55(1):33-45. PubMed ID: 26242379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
    Flinn IW; Kahl BS; Leonard JP; Furman RR; Brown JR; Byrd JC; Wagner-Johnston ND; Coutre SE; Benson DM; Peterman S; Cho Y; Webb HK; Johnson DM; Yu AS; Ulrich RG; Godfrey WR; Miller LL; Spurgeon SE
    Blood; 2014 May; 123(22):3406-13. PubMed ID: 24615776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
    Hewett YG; Uprety D; Shah BK
    J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
    Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
    Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Despas F; Chaouki M; de Barros S; Bonneau B; Allal B; Guillermet-Guibert J; Ysebaert L
    Leuk Lymphoma; 2024 Sep; 65(9):1378-1380. PubMed ID: 38747179
    [No Abstract]   [Full Text] [Related]  

  • 11. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.
    Bird ST; Tian F; Flowers N; Przepiorka D; Wang R; Jung TH; Kessler Z; Woods C; Kim B; Miller BW; Wernecke M; Kim C; McKean S; Gelperin K; MaCurdy TE; Kelman JA; Graham DJ
    JAMA Oncol; 2020 Feb; 6(2):248-254. PubMed ID: 31855259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
    Sharman JP; Coutre SE; Furman RR; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn IW; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Tausch E; Cramer P; Huang J; Mitra S; Hallek M; O'Brien SM; Stilgenbauer S
    J Clin Oncol; 2019 Jun; 37(16):1391-1402. PubMed ID: 30995176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Isidori A; Loscocco F; Visani G; Paolasini S; Scalzulli P; Musto P; Perrone T; Guarini A; Pastore D; Mazza P; Tonialini L; Pavone V; De Santis G; Tarantini G
    Br J Haematol; 2022 Nov; 199(3):339-343. PubMed ID: 36002151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
    Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
    Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
    Ma S; Chan RJ; Gu L; Xing G; Rajakumaraswamy N; Ruzicka BB; Wagner-Johnston ND
    Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e432-e448. PubMed ID: 33516721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
    Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
    Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.